Abstracts tagged "osteoporosis and rheumatoid arthritis"

Abstract Number: 2312 • 2012 ACR/ARHP Annual Meeting
Senescent T Cells Promote Bone Loss in Rheumatoid Arthritis
Johannes Fessler¹, Rusmir Husic², Elisabeth Lerchbaum³, Verena Schwetz³, Claudia Stiegler³, Barbara Obermayer-Pietsch³, Winfried B. Graninger⁴ and Christian Dejaco⁵, ¹Rheumatology and Immunology, Medical University Graz, Graz, Austria, ²Rheumatology, Medical University Graz, Graz, Austria, ³Division of Endocrinology and Metabolism, Medical University Graz, Graz, Austria, ⁴Internal medicine/Rheumatology and Immunology, Medical University Graz, Graz, Austria, ⁵Rheumatology, Southend University Hospital, Westcliff-on-Sea, United Kingdom
Background/Purpose: To study the influence of aged CD28-T cells on systemic osteoporosis in rheumatoid arthritis (RA) patients. Methods: Prospective, cross-sectional study on 100 patients with…
Abstract Number: 36 • 2012 ACR/ARHP Annual Meeting
Role of FK506 Binding Protein 5 in Osteoclast Differentiation
Miho Kimura¹, Tatsuo Nagai², Reiko Matsushita², Atsushi Hashimoto³, Toshiyuki Miyashita⁴ and Shunsei Hirohata⁵, ¹Rheumatology and Infectious diseases, Kitasato University School of Medicine, Sagamihara, Japan, ²Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Japan, ³Department of Rheumatology, National Hospital Organization Sagamihara Hospital, Kanagawa, Japan, ⁴Molecular Genetics, Kitasato University School of Medicine, Sagamihara, ⁵Int Med/Rheumatol & Infec Dis, Kitasato University School of Medicine, Sagamihara, Japan
Background/Purpose: RA is a chronic, systemic inflammatory disease characterized by the destruction of bone in the joints. Moreover, it is well appreciated that systemic osteoporosis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].